Dr. David R. Spigel, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 174
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Tennessee, Hsc, College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TN license 37373
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tristar Centennial Medical Center Nashville, TN
- Tristar Summit Medical Center Hermitage, TN
- Tristar Skyline Medical Center Nashville, TN
Medical groups
- Verdi Oncology Tennessee PC (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 174
- Services billed
- 39,878
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 7,400 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,269 | 58 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 537 | 112 |
| Blood test, comprehensive group of blood chemicals | 535 | 114 |
| Insertion of needle into vein for collection of blood sample | 385 | 95 |
| Injection, granisetron hydrochloride, 100 mcg | 350 | 17 |
| Administration of chemotherapy into vein, 1 hour or less | 279 | 94 |
| Established patient office or other outpatient visit, 40-54 minutes | 256 | 116 |
| Injection, carboplatin, 50 mg | 185 | 16 |
| Injection of additional new drug or substance into vein | 144 | 43 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Nashville, TN | 30 |
| Tagrisso (osimertinib mesylate) | 27 |
| Levothyroxine Sodium Other prescribers in Nashville, TN | 24 |
| Eliquis (apixaban) Other prescribers in Nashville, TN | 21 |
| Prochlorperazine Maleate Other prescribers in Nashville, TN | 19 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Nashville, TN | 17 |
| Oxycodone Hcl Other prescribers in Nashville, TN | 17 |
| Fentanyl Other prescribers in Nashville, TN | 14 |
| Lactulose Other prescribers in Nashville, TN | 14 |
| Tepmetko (tepotinib hcl) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 28 companies reported 67 payments worth $26,969 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $12,752 |
|---|---|
| GlaxoSmithKline, LLC. | $7,241 |
| AbbVie Inc. | $2,213 |
| Pfizer Inc. | $1,950 |
| AstraZeneca UK Limited | $1,271 |
| AstraZeneca Pharmaceuticals LP | $328 |
| Jazz Pharmaceuticals Inc. | $311 |
| Gilead Sciences, Inc. | $172 |
| Consulting Fee | $16,283 |
|---|---|
| Travel and Lodging | $8,777 |
| Food and Beverage | $1,909 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 16, 2025 | Consulting Fee | $11,003 |
| GlaxoSmithKline, LLC. Jun 11, 2025 | Travel and Lodging travel to Barcelona, Spain | $7,091 |
| AbbVie Inc. May 7, 2025 | Consulting Fee | $2,100 |
| Pfizer Inc. Sep 25, 2025 | Consulting Fee | $1,950 |
| AstraZeneca UK Limited Nov 13, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,230 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $581 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| Jazz Pharmaceuticals Inc. Dec 1, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Jersey City, NJ · in-kind | $311 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $19.98 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 52 industry-funded studies in 2025, from 28 companies. The companies reported $2,743,098 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors
Merck Sharp & Dohme LLC - A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced sol…
AstraZeneca UK Limited - A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma
Merck Sharp & Dohme LLC - An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Local…
Merck Sharp & Dohme LLC - Ph I Ib II of TIGIT aPDL 1
Genentech, Inc. - TAS-2940
Taiho Oncology, Inc. - PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC
Genentech, Inc. - A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase i open-label, multicenter study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of SAIL66 in patients with CLDN6-POSITIVE locally advanced or metastatic solid tumors
Chugai Pharmaceutical Co., Ltd. - A phase i open-label, multicenter study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of SAIL66 in patients with CLDN6-POSITIVE locally advanced or metastatic solid tumors
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.